(688428)"INNOCARE PHARMA LIMITED"Announcement on Convening the Q3 2026 Performance Briefing
Filed with SSE · Stock code 688428 · · 3 pages · Chinese
On 6ix: 6ix.com/news/688428innocare-pharma-limitedannouncement-on-convening-the-q3-2026-performance-briefing
Story so far
- Announcement on Vesting Results for the First Vesting Period of the Reserved Grant under the 2024 STAR Market Restricted Share Incentive Plan and Listing of Shares
- Announcement on the Progress of Acquisition of the Remaining Equity in a Controlled Subsidiary
- Announcement on the Satisfaction of Vesting Conditions for the First Vesting Period of the Reserved Grant under the 2024 STAR Market Restricted Share Incentive Plan
Earlier from InnoCare Pharma
- Indicative Announcement on Change in Equity Interests of Shareholder Holding More Than 5% of the Shares Reaching 1% Threshold
- Announcement on Vesting Results for the First Vesting Period of the Reserved Grant under the 2024 STAR Market Restricted Share Incentive Plan and Listing of Shares
- InnoCare Announces Approval of Clinical Trial of Novel Bispecific ADC ICP-B381 Targeting PSMA/ STEAP1 in China
- Announcement on the Progress of Acquisition of the Remaining Equity in a Controlled Subsidiary
- Announcement on the Satisfaction of Vesting Conditions for the First Vesting Period of the Reserved Grant under the 2024 STAR Market Restricted Share Incentive Plan
Later from InnoCare Pharma
- (688428)"INNOCARE PHARMA LIMITED"Report for Q3 2026
- InnoCare Announces First Patient Dosed in Head-to-Head Registrational Phase III Trial of Mesutoclax with Azacitidine versus Venetoclax with Azacitidine in Treatment Naive AML in China
- (688428)"INNOCARE PHARMA LIMITED"Announcement on Voluntary Disclosure of the Inclusion of Zurletrectinib in the 2026 National Reimbursement Drug List
Follow InnoCare Pharma into a list and get an email when it puts out news.
Follow InnoCare Pharma